drugset
Drugs / mRNA COVID-19
last change Jun 2023 re-read 2 minutes ago

mRNA COVID-19

also known as Pfizer-BioNtech mRNA- COVID-19

Messenger RNA (mRNA)

Developed for
COVID-19
Investigated by
Centers for Disease Control and Prevention · Children's Hospital Medical Center, Cincinnati · Duke University · Johns Hopkins University · Mark Loeb

Trials 2 · a red edge is where a trial was stopped

today NCT04978038 · Ph 4 NCT05028361 · Ph 4
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04978038 Aug → Nov 2022 COVID-19 Mark Loeb Unknown No outcome recorded
Phase 4 NCT05028361 Oct 2021 → Mar 2023 — Duke University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as mRNA COVID-19 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05028361 ↗
1

NCT04978038 ↗
Known as Pfizer-BioNtech mRNA- COVID-19 “Pfizer-BioNtech mRNA- COVID-19” NCT04978038 ↗
Modality Messenger RNA (mRNA) “Pfizer-BioNtech mRNA- COVID-19 vaccine” NCT04978038 ↗
Route Intramuscular “Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly” NCT04978038 ↗